Skip to main content

Research News

Pharma Courses
  • New troponin test improves heart attack diagnostics

    A new test has been developed in Turku, Finland, that helps in separating heart attack patients from those whose cardiac troponin values are elevated due to renal insufficiency. Blood sample tests for cardiac troponins are an important cornerstone in the diagnostics of heart attack, but the result may be elevated also due to other transient or chronic conditions, such as renal insufficiency, atrial fibrillation or strenuous physical exercise.

  • Weight loss and blood glucose are early indicators of pancreatic cancer

    Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests. Weight loss and increasing blood glucose levels are early indicators of pancreatic cancer and could lead to a more timely diagnosis, helping to improve survival rates.

  • mRNA COVID vaccine elevates cardiovascular risk, finds study

    A comprehensive review and meta-analysis of published research confirm that young adults (40 years old and younger) have a slightly elevated risk for myocarditis or pericarditis after mRNA COVID-19 vaccination. The analysis is reported in a new study in the American Journal of Preventive Medicine, published by Elsevier.

  • The origin-of-life molecule, a key to cancer research

    A study by researchers at the Biomedical Institute of Seville (IBIS) and the University of Seville, in collaboration with the Danish Cancer Society, revealed that inhibiting RNA synthesis after radiation therapy facilitates the death of tumour cells. The study has been published in the prestigious journal Nature Communications.

  • Antioxidant benefits of honey explored

    Citrus honey has an increased abundance of antioxidants in comparison to other standard types of honey, according to a new study by University of the West of Scotland (UWS).

    Antioxidants are chemicals that reduce or prevent the effects of free radicals: unstable molecules that can damage cells, causing illness, disease, and ageing.

  • Study overcomes the obstacles to treatment for colon cancer

    Colorectal cancer is one of the most common cancers. Its treatment is mainly based on chemotherapy. However, over time, chemotherapy induces resistance in the majority of patients, who end up being unresponsive to the drugs. As a result, the five-year survival rate for those affected is still low. After succeeding in reproducing this resistance in the laboratory, a team from the University of Geneva (UNIGE) has found a way to overcome it.

  • Three-dose hepatitis B vaccine regimen protects people with HIV

    A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsors the ongoing Phase 3 ACTG A5379 clinical study.

  • Two drugs reverse key pancreatic cancer step in the lab

    Pancreatic cancer often lurks as a silent disease. With no known symptoms, it can progress undetected and spread to other organs.

    According to the National Cancer Institute, more than 60,000 Americans will be diagnosed with pancreatic cancer this year, and only about 1 in 10 of those diagnosed will survive the next five years.  The disease ranks as the third leading cause of cancer deaths in the U.S. because it is rarely detected in the early stages when treatment options are most effective.

  • Researchers find protein complex that regulates migration of neurons and neuroblastoma cancer cells

    During brain development, neurons have to migrate long distances through complex environments until they reach their final destination. In order to find guidance, they must establish several interactions —which are still hard to study— between their receptors and the surrounding molecules.

  • What will the future of the bioeconomy look like?

    The 2012 EU Bioeconomy Strategy is delivering on key actions and has seen a two-fold increase in EU R&I funding for the bioeconomy under Horizon 2020, today Horizon Europe.

Subscribe to Research News